Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 2
1972 4
1973 2
1974 1
1975 1
1980 3
1981 2
1982 1
1983 3
1986 1
1987 3
1988 3
1989 2
1990 5
1991 1
1993 1
1994 4
1995 2
1997 1
1998 2
1999 2
2000 6
2001 5
2002 2
2003 2
2006 1
2007 1
2008 1
2009 1
2010 2
2012 1
2016 3
2017 2
2018 3
2019 3
2020 1
2021 3
2022 7
2023 9
2024 10
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
CDK4/6 inhibitors: The Devil is in the Detail.
Magge T, Rajendran S, Brufsky AM, Foldi J. Magge T, et al. Among authors: foldi j. Curr Oncol Rep. 2024 Jun;26(6):665-678. doi: 10.1007/s11912-024-01540-7. Epub 2024 May 7. Curr Oncol Rep. 2024. PMID: 38713311 Review.
Pharmacology and pharmacokinetics of elacestrant.
Beumer JH, Foldi J. Beumer JH, et al. Among authors: foldi j. Cancer Chemother Pharmacol. 2023 Aug;92(2):157-163. doi: 10.1007/s00280-023-04550-7. Epub 2023 Jun 14. Cancer Chemother Pharmacol. 2023. PMID: 37314500 Free PMC article.
Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO).
Schmitz KH, Brown JC, Irwin ML, Robien K, Scott JM, Berger NA, Caan B, Cercek A, Crane TE, Evans SR, Ligibel JA, Meyerhardt JA, Agurs-Collins T, Basen-Engquist K, Bea JW, Cai SF, Cartmel B, Chinchilli VM, Demark-Wahnefried W, Dieli-Conwright CM, DiPietro L, Doerksen SE, Edelstein SL, Elena J, Evans W, Ferrucci LM, Foldi J, Freylersythe S, Furberg H, Jones LW, Levine R, Moskowitz CS, Owusu C, Penedo F, Rabin BA, Ratner E, Rosenzweig M, Salz T, Sanft T, Schlumbrecht M, Spielmann G, Thomson CA, Tjaden AH, Weiser MR, Yang S, Yu AF, Perna FM; ENICTO Consortium. Schmitz KH, et al. Among authors: foldi j. J Natl Cancer Inst. 2025 Jan 1;117(1):9-19. doi: 10.1093/jnci/djae177. J Natl Cancer Inst. 2025. PMID: 39118255 Free PMC article.
Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.
Shah OS, Nasrazadani A, Foldi J, Atkinson JM, Kleer CG, McAuliffe PF, Johnston TJ, Stallaert W, da Silva EM, Selenica P, Dopeso H, Pareja F, Mandelker D, Weigelt B, Reis-Filho JS, Bhargava R, Lucas PC, Lee AV, Oesterreich S. Shah OS, et al. Among authors: foldi j. Proc Natl Acad Sci U S A. 2024 Jul 30;121(31):e2322068121. doi: 10.1073/pnas.2322068121. Epub 2024 Jul 23. Proc Natl Acad Sci U S A. 2024. PMID: 39042692 Free PMC article.
Cancer Relevance of Human Genes.
Qing T, Mohsen H, Cannataro VL, Marczyk M, Rozenblit M, Foldi J, Murray M, Townsend JP, Kluger Y, Gerstein M, Pusztai L. Qing T, et al. Among authors: foldi j. J Natl Cancer Inst. 2022 Jul 11;114(7):988-995. doi: 10.1093/jnci/djac068. J Natl Cancer Inst. 2022. PMID: 35417011 Free PMC article.
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Blenman KRM, et al. Among authors: foldi j. Clin Cancer Res. 2022 Jun 13;28(12):2587-2597. doi: 10.1158/1078-0432.CCR-21-3215. Clin Cancer Res. 2022. PMID: 35377948 Free PMC article. Clinical Trial.
Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.
Shah OS, Nasrazadani A, Foldi J, Atkinson JM, Kleer CG, McAuliffe PF, Johnston TJ, Stallaert W, da Silva EM, Selenica P, Dopeso H, Pareja F, Mandelker D, Weigelt B, Reis-Filho JS, Bhargava R, Lucas PC, Lee AV, Oesterreich S. Shah OS, et al. Among authors: foldi j. bioRxiv [Preprint]. 2024 Jun 16:2023.09.09.557013. doi: 10.1101/2023.09.09.557013. bioRxiv. 2024. Update in: Proc Natl Acad Sci U S A. 2024 Jul 30;121(31):e2322068121. doi: 10.1073/pnas.2322068121 PMID: 38915645 Free PMC article. Updated. Preprint.
112 results